Similarly, the selective, non-steroidal mineralocorticoid receptor antagonist Finerenone has exhibited cardiorenal protective effects in individuals with T2D and CKD [129, 130]. The gene discussed is NR3C2; the disease is type 2 diabetes mellitus.